Allergan reported $1.06 diluted earnings per share attributable to stockholders compared to $0.90 diluted earnings per share attributable to stockholders for the fourth quarter of 2011.

Allergan reported $1.15 non-GAAP diluted earnings per share attributable to stockholders compared to $1.00 non-GAAP diluted earnings per share attributable to stockholders for the fourth quarter of 2011, a 15.0 percent increase.

Diluted and non-GAAP diluted earnings per share for the fourth quarter of 2012 exclude the full year 2012 impact of the U.S. Research and Development tax credit, which was signed into law on January 2, 2013 and retroactively reinstated to January 1, 2012. The estimated impact of the Research and Development tax credit on net earnings attributable to Allergan for the full year 2012, which will be reported in Allergan’s operating results in the first quarter of 2013, was approximately $17.3 million, or $0.06 diluted earnings per share based on weighted average diluted shares outstanding of 307.1 million for the full year 2012.

Allergan reported $1,484.6 million total product net sales. Total product net sales increased 7.4 percent compared to total product net sales in the fourth quarter of 2011. On a constant currency basis, total product net sales increased 8.1 percent compared to total product net sales in the fourth quarter of 2011.

Total specialty pharmaceuticals net sales increased 8.2 percent, or 9.0 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the fourth quarter of 2011.

Total medical devices net sales increased 2.9 percent, or 3.6 percent on a constant currency basis, compared to total medical devices net sales in the fourth quarter of 2011.

On November 16, 2012, Allergan announced that it had entered into a definitive agreement with SkinMedica, Inc. to acquire the privately held company’s topical aesthetics skin care business. On December 19, 2012, Allergan announced completion of the acquisition of SkinMedica, Inc. Under the terms of the agreement, Allergan paid approximately $350 million (subject to certain adjustments) for the business, which includes a variety of “physician dispensed” non-prescription aesthetic skin care products and prescription products.

On November 19, 2012, Allergan received the European Commission decision for a new preservative-free formulation of LUMIGAN^® (Bimatoprost Ophthalmic Solution) 0.03% in single-dose containers for the 27 countries of the European Union. LUMIGAN^® is licensed for the reduction of elevated intraocular pressure (IOP) in adults with chronic open-angle glaucoma and ocular hypertension and is now available in a formulation for those patients who require a preservative-free treatment.

In December 2012, the U.S. District Court in Santa Ana, California granted Allergan’s summary judgment motions, finding that Lifetech’s Rapidlash^®, Cosmetic Alchemy’s LiLash^®, and Rocasuba’s neuLash^® lines of products are drugs sold without approval and are therefore misbranded in violation of California law as well as the federal statutes which California law incorporates. On October 12, 2012, the court denied a motion by Athena Cosmetics, Inc. for reconsideration of the court’s decision to grant Allergan’s motion for summary judgment against Athena Cosmetics, Inc. on our unfair competition cause of action. In July 2012, the court granted Allergan’s summary judgment motion, finding that Athena’s Revitalash^® line of products are drugs sold without approval and are therefore misbranded in violation of California law as well as the federal statutes which California law incorporates.

On December 19, 2012, Allergan announced that BOTOX^® (botulinum toxin type A) received a positive opinion from the Irish Medicines Board for the treatment of idiopathic overactive bladder (OAB) with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to, or are intolerant of, anticholinergic medications. This is an important step towards securing national licenses in the 14 European countries involved in the Mutual Recognition Procedure.

Allergan submitted a supplemental biologics license application (sBLA) with the U.S. Food and Drug Administration (FDA) for the use of BOTOX^® Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines (crow’s feet lines) in adults treated either alone or simultaneously with glabellar lines.

On January 18, 2013, Allergan announced that the FDA approved BOTOX^® (onabotulinumtoxinA) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

On January 22, 2013, Allergan and MAP Pharmaceuticals announced that they entered into a definitive merger agreement whereby Allergan will acquire 100% of the shares of MAP Pharmaceuticals for a price of $25.00 per share. MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies in Neurology, including Levadex^®, an orally inhaled drug for the potential acute treatment of migraine in adults. Levadex^® is currently under review with the FDA.

In January 2013, Allergan restructured its collaboration agreement with Spectrum Pharmaceuticals, Inc. (“Spectrum”) pursuant to which Spectrum reacquired all rights from Allergan under the collaboration agreement in exchange for agreeing to pay Allergan a royalty on future net sales of specified products. Going forward, Allergan will have no further obligations under the agreement to share development costs or perform any development, regulatory or other activities.

On February 1, 2013, Allergan completed its previously announced review of strategic options for maximizing the value of its obesity intervention business, and has formally committed to pursue a sale of that business unit. Accordingly, Allergan will begin to consider offers for the sale of that business unit and currently expects to execute a signed agreement in the first half of 2013. As a result of Allergan’s approved plan to sell its obesity intervention business unit, beginning in the first quarter of 2013, Allergan expects to report the financial results from that business unit in discontinued operations in its statement of earnings and balance sheet, and intends to retrospectively adjust its prior period statements of earnings and its balance sheet as of December 31, 2012 to reflect the classification of assets and liabilities held for sale as discontinued operations. In the first quarter of 2013, Allergan expects to report income from discontinued operations and a separate expected disposal loss from the write-down to fair value of the net assets held for sale. Allergan is currently unable to estimate the range of the expected disposal loss. As previously stated, Allergan intends to offset any potential earnings dilution related to this transaction.

Total product net sales between $5,900 million and $6,200 million, which excludes the obesity intervention business.

Total specialty pharmaceuticals net sales between $5,100 million and $5,340 million.

Total medical devices net sales between $800 million and $860 million.

ALPHAGAN^® franchise product net sales between $440 million and $470 million.

LUMIGAN^® franchise product net sales between $630 million and $660 million.

RESTASIS^® product net sales between $830 million and $870 million.

BOTOX^® product net sales between $1,900 million and $2,000 million.

LATISSE^® product net sales at approximately $110 million.

Breast aesthetics product net sales between $390 million and $420 million.

Facial aesthetics product net sales between $410 million and $440 million.

Non-GAAP cost of sales to product net sales ratio at approximately 13.5%.

Non-GAAP other revenue at approximately $90 million.

Non-GAAP selling, general and administrative expenses to product net sales ratio between 37% and 38%.

Non-GAAP research and development expenses to product net sales ratio at approximately 16.5%.

Non-GAAP amortization of intangible assets at approximately $25 million. This expectation excludes the amortization of certain intangible assets associated with business combinations, asset purchases and product licenses.

Non-GAAP diluted earnings per share attributable to stockholders between $4.75 and $4.83, which excludes the 2012 impact of the Research and Development tax credit, which was signed into law on January 2, 2013 and retroactively reinstated to January 1, 2012, and excludes the dilutive impact of the proposed acquisition of MAP Pharmaceuticals as discussed on the January 23, 2013 conference call.

Diluted shares outstanding at approximately 303 million.

Effective tax rate on non-GAAP earnings between 26% and 27%.

Total product net sales between $1,375 million and $1,450 million, which excludes the obesity intervention business.

Non-GAAP diluted earnings per share attributable to stockholders between $0.94 and $0.96, which excludes the 2012 impact of the Research and Development tax credit, which was signed into law on January 2, 2013 and retroactively reinstated to January 1, 2012, and excludes the dilutive impact of the proposed acquisition of MAP Pharmaceuticals as discussed on the January 23, 2013 conference call.

In millions, except per share amounts

Revenues

Product net sales

Other revenues

Operating costs and expenses

Cost of sales (excludes amortization of
intangible assets)

Selling, general and administrative

Research and development

Amortization of intangible assets

Impairment of intangible assets and related costs

Restructuring charges

Operating income

Non-operating income (expense)

Interest income

Interest expense

Other, net

Earnings before income taxes

Provision for income taxes

Net earnings

Net earnings (loss) attributable to noncontrolling interest

Net earnings attributable to Allergan, Inc.

Net earnings per share attributable to
Allergan, Inc. stockholders:

Basic

Diluted

Weighted average number of common shares outstanding:

Basic

Diluted

Selected ratios as a percentage of product net sales

Cost of sales (excludes amortization of
intangible assets)

Selling, general and administrative

Research and development

Impairment of an in-process research and development asset related to technology acquired in connection with the 2011 acquisition of Vicept Therapeutics, Inc. of $17.0 million and a prepaid royalty asset associated with the Sanctura^® franchise of $5.3 million

Non-GAAP pre-tax adjustments of $44.0 million

Change in estimated taxes related to uncertain tax positions included in prior year filings

it does not reflect cash expenditures, or future requirements, for expenditures relating to restructurings, legal settlements, and certain acquisitions, including severance and facility transition costs associated with acquisitions;

it does not reflect asset impairment charges or gains or losses on the disposition of assets associated with restructuring and business exit activities;

it does not reflect the tax benefit or tax expense associated with the items indicated;

it does not reflect the impact on earnings of charges or income resulting from certain matters Allergan considers not to be indicative of its on-going operations; and

other companies in Allergan’s industry may calculate non-GAAP earnings differently than it does, which may limit its usefulness as a comparative measure.

In millions, except per share amounts

Revenues

Product net sales

Other revenues

Operating costs and expenses

Cost of sales (excludes amortization of
intangible assets)

Selling, general and administrative

Research and development

Amortization of intangible assets

Impairment of intangible assets and related costs

Restructuring charges

Operating income

Non-operating income (expense)

Interest income

Interest expense

Other, net

Earnings before income taxes

Provision for income taxes

Net earnings

Net earnings attributable to noncontrolling interest

Net earnings attributable to Allergan, Inc.

Net earnings per share attributable to
Allergan, Inc. stockholders:

Basic

Diluted

Weighted average number of common
shares outstanding:

Basic

Diluted

Selected ratios as a percentage of product net sales

Cost of sales (excludes amortization of
intangible assets)

Selling, general and administrative

Research and development

Impairment of an in-process research and development asset related to technology acquired in connection with the 2011 acquisition of Vicept Therapeutics, Inc. of $17.0 million and a prepaid royalty asset associated with the Sanctura^® franchise of $5.3 million

Non-GAAP pre-tax adjustments of $234.7 million

Change in estimated taxes related to uncertain tax positions included in
prior year filings

Fixed asset impairment of $2.2 million and a gain of $9.4 million from the substantially complete liquidation of Allergan’s investment in a foreign subsidiary included in selling, general and administrative expenses, and intangible asset impairment of $16.1 million resulting from the discontinued development of the Easyband^™ Remote Adjustable Gastric Band System, a technology acquired by Allergan in the 2007 EndoArt SA acquisition

Additional costs of $3.3 million for the termination of a third-party agreement primarily related to the promotion of Sanctura XR^® associated with the impairment of the Sanctura^® assets in the third quarter of 2010

in millions

Assets

Cash and equivalents

Short-term investments

Trade receivables, net

Inventories

Other current assets

Total current assets

Property, plant and equipment, net

Intangible assets, net

Goodwill

Other noncurrent assets

Total assets

Liabilities and equity

Notes payable

Accounts payable

Other accrued expenses

Total current liabilities

Long-term debt

Other liabilities

Equity:

Allergan, Inc. stockholders’ equity

Noncontrolling interest

Total equity

Total liabilities and equity

DSO

DOH

Cash and equivalents and short-term investments

Total notes payable and long-term debt

Cash and equivalents and short-term investments, net of debt

Debt-to-capital percentage

In millions, except per share amounts

Net earnings attributable to Allergan, Inc.

Non-GAAP pre-tax adjustments:

Expenses (income) from changes in fair value of contingent consideration and integration and transaction costs associated with business combinations

External costs for stockholder derivative and tax litigation associated with the DOJ settlement

Expenses related to the realignment of various business functions and the restructuring of the obesity intervention business

Transaction costs associated with the license and collaboration agreements with Molecular Partners AG for technology that has not achieved regulatory approval

Amortization of intangible assets

Impairment of an in-process research and development asset related to technology acquired in connection with the 2011 acquisition of Vicept Therapeutics, Inc. and a prepaid royalty asset associated with the Sanctura^® franchise